Roche
NEWS
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
Bristol-Myers Squibb announced that it has expanded its relationship with Flatiron Health, extending a three-year collaboration agreement.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
The FDA granted Pfizer’s Trumenba, a vaccine for meningococcal B disease in children ages one to nine years, Breakthrough Therapy Designation and declined to approve its biosimilar of Roche’s Herceptin for breast cancer.
Earlier this month Roche acquired a regenerative therapy program for MS from Inception Sciences and now today Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
JOBS
IN THE PRESS